Tyra Biosciences Past Earnings Performance
Past criteria checks 0/6
Tyra Biosciences's earnings have been declining at an average annual rate of -49.1%, while the Biotechs industry saw earnings growing at 12.7% annually.
Key information
-49.1%
Earnings growth rate
41.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -33.8% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
We're Not Very Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Rate
Jan 13
We Think Tyra Biosciences (NASDAQ:TYRA) Can Afford To Drive Business Growth
Sep 27Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans
Jun 13Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans
Feb 23Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans
Nov 09Tyra Biosciences GAAP EPS of -$0.36
Aug 04Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation
Jul 21Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation
Mar 31Companies Like Tyra Biosciences (NASDAQ:TYRA) Are In A Position To Invest In Growth
Dec 15Revenue & Expenses BreakdownBeta
How Tyra Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -69 | 17 | 63 |
| 30 Sep 23 | 0 | -59 | 17 | 52 |
| 30 Jun 23 | 0 | -51 | 15 | 44 |
| 31 Mar 23 | 0 | -52 | 15 | 44 |
| 31 Dec 22 | 0 | -55 | 16 | 43 |
| 30 Sep 22 | 0 | -52 | 14 | 40 |
| 30 Jun 22 | 0 | -46 | 12 | 34 |
| 31 Mar 22 | 0 | -37 | 10 | 27 |
| 31 Dec 21 | 0 | -26 | 6 | 21 |
| 30 Sep 21 | 0 | -20 | 4 | 16 |
| 30 Jun 21 | 0 | -16 | 3 | 13 |
| 31 Mar 21 | 0 | -12 | 2 | 10 |
| 31 Dec 20 | 0 | -9 | 2 | 7 |
Quality Earnings: TYRA is currently unprofitable.
Growing Profit Margin: TYRA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TYRA is unprofitable, and losses have increased over the past 5 years at a rate of 49.1% per year.
Accelerating Growth: Unable to compare TYRA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TYRA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: TYRA has a negative Return on Equity (-33.85%), as it is currently unprofitable.